Skip to Content
Upcoming Webinar

Tislelizumab-jsgr: A Unique PD-1 Inhibitor for ESCC and Gastric Cancers

Date: June 18, 2025 | 2:00 PM

Tislelizumab-jsgr is a PD-1 inhibitor with a unique binding profile—designed to support strong and sustained T-cell activation. It’s gaining attention for its role in treating advanced gastrointestinal cancers.

Join us for a focused discussion on how tislelizumab fits into the evolving treatment landscape for esophageal squamous cell carcinoma (ESCC) and gastric/gastroesophageal junction adenocarcinoma (G/GEJC)—backed by evidence and clinical insight.

What we’ll cover:

  • What makes tislelizumab different: mechanism of action and clinical relevance
  • RATIONALE 302 & 305 trial data: efficacy and safety in both lines of therapy
  • Biomarker and patient selection strategies
  • Dosing, administration, and management of immune-related adverse events
  • Patient access and support through myBeOne Support™

 

For additional information or login assistance, reach out to NCODA’s Jonathan Rivera.